1. Will Gut Microbiota Help Design the Next Generation of GLP-1-Based Therapies for Type 2 Diabetes?
- Author
-
Sandrine P. Claus
- Subjects
0301 basic medicine ,endocrine system ,Physiology ,030209 endocrinology & metabolism ,Type 2 diabetes ,Gut flora ,Nitric Oxide ,Incretins ,03 medical and health sciences ,0302 clinical medicine ,Glucagon-Like Peptide 1 ,Gut bacteria ,Diabetes mellitus ,medicine ,Receptors, Glucagon ,Animals ,Humans ,Hypoglycemic Agents ,Molecular Biology ,biology ,digestive, oral, and skin physiology ,Cell Biology ,biology.organism_classification ,Nitric oxide metabolism ,medicine.disease ,Gastrointestinal Microbiome ,030104 developmental biology ,Cell metabolism ,Diabetes Mellitus, Type 2 ,Immunology ,Enteric nervous system ,No signaling ,hormones, hormone substitutes, and hormone antagonists ,Signal Transduction - Abstract
Glucagon-like peptide one (GLP-1)-based therapies for reducing hyperglycemia in type 2 diabetic patients are efficient, though some individuals develop GLP-1 resistance. In a recent issue of Cell Metabolism, Grasset et al. (2017) demonstrated that GLP-1 sensitivity is modulated by gut bacteria through NO signaling in the enteric nervous system.
- Published
- 2017